Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$2.70 USD
+0.26 (10.45%)
Updated Aug 12, 2024 03:59 PM ET
After-Market: $2.78 +0.09 (3.15%) 5:38 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Phio Pharmaceuticals Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 11 | 14 | 9 | 9 |
Income After Depreciation & Amortization | -11 | -11 | -14 | -9 | -9 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -11 | -11 | -13 | -9 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | -11 | -13 | -9 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | -11 | -13 | -9 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | -11 | -13 | -9 | -9 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -11 | -14 | -9 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.23 | 0.13 | 0.12 | 0.04 | 0.00 |
Diluted EPS Before Non-Recurring Items | -46.80 | -90.91 | -112.38 | -207.46 | -2,088.69 |
Diluted Net EPS (GAAP) | -46.80 | -90.91 | -112.38 | -207.46 | -2,088.68 |
Fiscal Year end for Phio Pharmaceuticals Corp falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.21 | 1.78 | 2.78 | 2.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.21 | -1.78 | -2.78 | -2.54 |
Non-Operating Income | NA | 0.06 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.15 | -1.90 | -2.78 | -2.55 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.15 | -1.90 | -2.78 | -2.55 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.15 | -1.90 | -2.78 | -2.55 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.51 | 0.23 | 0.27 | 0.19 |
Diluted EPS Before Non-Recurring Items | NA | -4.23 | -1.53 | -10.26 | -13.23 |
Diluted Net EPS (GAAP) | NA | -4.23 | 5.04 | -10.26 | -13.23 |